{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T06:22:45Z","timestamp":1794378165233,"version":"4.9.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T00:00:00Z","timestamp":1663286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T00:00:00Z","timestamp":1663286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Rheumatoid arthritis (RA) patients present with abnormal methylation patterns in their fibroblast-like synoviocytes (FLS). Given that DNA demethylation is critical for producing DNA methylation patterns, we hypothesized that DNA demethylation may facilitate RA progression. Therefore, we designed this study to examine the role of DNA dioxygenase family, Ten-Eleven translocation (TET1\/2\/3), in the pathological process of RA.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Synovial tissues and FLS were obtained from patients with RA and Osteoarthritis. K\/BxN serum-induced arthritis was induced in Wild-type (WT) and <jats:italic>TET3<\/jats:italic> heterozygous-deficient (<jats:italic>TET3<\/jats:italic><jats:sup><jats:italic>+\/\u2212<\/jats:italic><\/jats:sup>) C57BL\/6 mice.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We found that both TET3 and 5-hydroxymethylcytosine (5hmC) were upregulated in synovitis tissues from RA patients and confirmed this upregulation in the cultured FLS derived from synovitis tissues. Tumor necrosis factor \u03b1 (TNF\u03b1) upregulated TET3 and 5hmC levels in cultured FLS, and the stimulated FLS exhibited high cell mobility with increased transcription of cellular migration-related factors such as C-X-C motif chemokine ligand 8 (CXCL8) and C-C motif chemokine ligand 2 (CCL2) in a TET3-dependent manner. In addition, <jats:italic>TET3<\/jats:italic> haploinsufficiency lowered RA progression in a mouse model of serum-induced arthritis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Based on these findings, we can assume that TET3-mediated DNA demethylation acts as an epigenetic regulator of RA progression.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-022-02908-5","type":"journal-article","created":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T10:04:54Z","timestamp":1663322694000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Role of DNA dioxygenase Ten-Eleven translocation 3 (TET3) in rheumatoid arthritis progression"],"prefix":"10.1186","volume":"24","author":[{"given":"Akio","family":"Kawabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Yamagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeaki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-ichi","family":"Tsukada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Ohmura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Nakayamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,16]]},"reference":[{"key":"2908_CR1","doi-asserted-by":"crossref","unstructured":"Schett G, Tanaka Y, Isaacs JD. Why remission is not enough: underlying disease mechanisms in RA that prevent cure.\u00a0Nat Rev Rheumatol. 2020;17(3):135\u201344.","DOI":"10.1038\/s41584-020-00543-5"},{"key":"2908_CR2","first-page":"18001","volume":"4","author":"JS Smolen","year":"2018","unstructured":"Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev. 2018;4:18001 Disease primers.","journal-title":"Nat Rev"},{"issue":"4","key":"2908_CR3","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00281-017-0621-5","volume":"39","author":"C Ospelt","year":"2017","unstructured":"Ospelt C, Gay S, Klein K. Epigenetics in the pathogenesis of RA. Sem Immunopathol. 2017;39(4):409\u201319.","journal-title":"Sem Immunopathol"},{"issue":"2","key":"2908_CR4","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.immuni.2017.02.006","volume":"46","author":"GS Firestein","year":"2017","unstructured":"Firestein GS, McInnes IB. Immunopathogenesis of Rheumatoid Arthritis. Immunity. 2017;46(2):183\u201396.","journal-title":"Immunity"},{"issue":"1","key":"2908_CR5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nrrheum.2012.190","volume":"9","author":"N Bottini","year":"2013","unstructured":"Bottini N, Firestein GS. Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors. Nat Rev Rheumatol. 2013;9(1):24\u201333.","journal-title":"Nat Rev Rheumatol"},{"key":"2908_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/JIR.S129027","volume":"12","author":"E Stylianou","year":"2019","unstructured":"Stylianou E. Epigenetics of chronic inflammatory diseases. J Inflammation Res. 2019;12:1\u201314.","journal-title":"J Inflammation Res"},{"key":"2908_CR7","doi-asserted-by":"crossref","unstructured":"Zeng Y, Chen T. DNA methylation reprogramming during mammalian development. Genes. 2019;10(4):257.","DOI":"10.3390\/genes10040257"},{"issue":"1","key":"2908_CR8","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1136\/annrheumdis-2012-201526","volume":"72","author":"K Nakano","year":"2013","unstructured":"Nakano K, Whitaker JW, Boyle DL, Wang W, Firestein GS. DNA methylome signature in rheumatoid arthritis. Ann Rheum Dis. 2013;72(1):110\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2908_CR9","doi-asserted-by":"publisher","first-page":"539","DOI":"10.2217\/epi.15.15","volume":"7","author":"JR Glossop","year":"2015","unstructured":"Glossop JR, Haworth KE, Emes RD, et al. DNA methylation profiling of synovial fluid FLS in rheumatoid arthritis reveals changes common with tissue-derived FLS. Epigenomics. 2015;7(4):539\u201351.","journal-title":"Epigenomics"},{"key":"2908_CR10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jaut.2012.12.005","volume":"41","author":"L de la Rica","year":"2013","unstructured":"de la Rica L, Urquiza JM, Gomez-Cabrero D, et al. Identification of novel markers in rheumatoid arthritis through integrated analysis of DNA methylation and microRNA expression. J Autoimmunity. 2013;41:6\u201316.","journal-title":"J Autoimmunity"},{"issue":"1","key":"2908_CR11","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1038\/s41467-018-04310-9","volume":"9","author":"R Ai","year":"2018","unstructured":"Ai R, Laragione T, Hammaker D, et al. Comprehensive epigenetic landscape of rheumatoid arthritis fibroblast-like synoviocytes. Nat Commun. 2018;9(1):1921.","journal-title":"Nat Commun"},{"issue":"3","key":"2908_CR12","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.4049\/jimmunol.1202572","volume":"190","author":"K Nakano","year":"2013","unstructured":"Nakano K, Boyle DL, Firestein GS. Regulation of DNA methylation in rheumatoid arthritis synoviocytes. J Immunol (Baltimore, Md. : 1950). 2013;190(3):1297\u2013303.","journal-title":"J Immunol (Baltimore, Md. : 1950)"},{"issue":"12","key":"2908_CR13","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1002\/art.25018","volume":"60","author":"E Karouzakis","year":"2009","unstructured":"Karouzakis E, Gay RE, Michel BA, Gay S, Neidhart M. DNA hypomethylation in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum. 2009;60(12):3613\u201322.","journal-title":"Arthritis Rheum."},{"issue":"1","key":"2908_CR14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrrheum.2015.169","volume":"12","author":"GD Kalliolias","year":"2016","unstructured":"Kalliolias GD, Ivashkiv LB. TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nat Rev Rheumatol. 2016;12(1):49\u201362.","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"2908_CR15","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1093\/rheumatology\/kev422","volume":"55","author":"JY Choe","year":"2016","unstructured":"Choe JY, Hun Kim J, Park KY, Choi CH, Kim SK. Activation of dickkopf-1 and focal adhesion kinase pathway by tumour necrosis factor alpha induces enhanced migration of fibroblast-like synoviocytes in rheumatoid arthritis. Rheumatology (Oxford, England). 2016;55(5):928\u201338.","journal-title":"Rheumatology (Oxford, England)"},{"issue":"4","key":"2908_CR16","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S1074-7613(00)80045-X","volume":"10","author":"AS Korganow","year":"1999","unstructured":"Korganow AS, Ji H, Mangialaio S, et al. From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity. 1999;10(4):451\u201361.","journal-title":"Immunity"},{"key":"2908_CR17","doi-asserted-by":"publisher","first-page":"15876","DOI":"10.1038\/srep15876","volume":"5","author":"Y Tsukada","year":"2015","unstructured":"Tsukada Y, Akiyama T, Nakayama KI. Maternal TET3 is dispensable for embryonic development but is required for neonatal growth. Sci Rep. 2015;5:15876.","journal-title":"Sci Rep"},{"issue":"11","key":"2908_CR18","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1242\/dev.070771","volume":"139","author":"L Tan","year":"2012","unstructured":"Tan L, Shi YG. Tet family proteins and 5-hydroxymethylcytosine in development and disease. Development (Cambridge, England). 2012;139(11):1895\u2013902.","journal-title":"Development (Cambridge, England)"},{"issue":"9","key":"2908_CR19","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1136\/annrheumdis-2018-214783","volume":"78","author":"C Loh","year":"2019","unstructured":"Loh C, Park SH, Lee A, Yuan R, Ivashkiv LB, Kalliolias GD. TNF-induced inflammatory genes escape repression in fibroblast-like synoviocytes: transcriptomic and epigenomic analysis. Ann Rheum Dis. 2019;78(9):1205\u201314.","journal-title":"Ann Rheum Dis"},{"key":"2908_CR20","doi-asserted-by":"crossref","unstructured":"Tsuchiya H, Ota M, Sumitomo S, et al. Parsing multiomics landscape of activated synovial fibroblasts highlights drug targets linked to genetic risk of rheumatoid arthritis. Ann Rheum Dis. 2021;80(4):440\u201350.","DOI":"10.1136\/annrheumdis-2020-218189"},{"issue":"3","key":"2908_CR21","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1002\/jbmr.2711","volume":"31","author":"SE Taylor","year":"2016","unstructured":"Taylor SE, Li YH, Smeriglio P, Rath M, Wong WH, Bhutani N. Stable 5-Hydroxymethylcytosine (5hmC) Acquisition Marks Gene Activation During Chondrogenic Differentiation. J Bone Min Res. 2016;31(3):524\u201334.","journal-title":"J Bone Min Res"},{"issue":"7690","key":"2908_CR22","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nature25434","volume":"554","author":"Q Shen","year":"2018","unstructured":"Shen Q, Zhang Q, Shi Y, et al. Tet2 promotes pathogen infection-induced myelopoiesis through mRNA oxidation. Nature. 2018;554(7690):123\u20137.","journal-title":"Nature"},{"issue":"7639","key":"2908_CR23","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature20810","volume":"542","author":"DA Rao","year":"2017","unstructured":"Rao DA, Gurish MF, Marshall JL, et al. Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis. Nature. 2017;542(7639):110\u20134.","journal-title":"Nature"},{"issue":"2","key":"2908_CR24","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1002\/jcb.25282","volume":"117","author":"UA Khan","year":"2016","unstructured":"Khan UA, Hashimi SM, Bakr MM, Forwood MR, Morrison NA. CCL2 and CCR2 are Essential for the Formation of Osteoclasts and Foreign Body Giant Cells. J Cell Biochem. 2016;117(2):382\u20139.","journal-title":"J Cell Biochem"},{"issue":"3","key":"2908_CR25","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/art.20932","volume":"52","author":"AE Koch","year":"2005","unstructured":"Koch AE. Chemokines and their receptors in rheumatoid arthritis: future targets? Arthritis Rheum. 2005;52(3):710\u201321.","journal-title":"Arthritis Rheum"},{"issue":"Suppl 2","key":"2908_CR26","first-page":"ii3","volume":"42","author":"JM Dayer","year":"2003","unstructured":"Dayer JM. The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis. Rheumatology (Oxford, England). 2003;42(Suppl 2):ii3\u201310.","journal-title":"Rheumatology (Oxford, England)"},{"issue":"7","key":"2908_CR27","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/s41590-019-0378-1","volume":"20","author":"F Zhang","year":"2019","unstructured":"Zhang F, Wei K, Slowikowski K, et al. Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry. Nat Immunol. 2019;20(7):928\u201342.","journal-title":"Nat Immunol"},{"issue":"4","key":"2908_CR28","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1152\/physrev.00046.2011","volume":"92","author":"J Lennartsson","year":"2012","unstructured":"Lennartsson J, Ronnstrand L. Stem cell factor receptor\/c-Kit: from basic science to clinical implications. Physiol Rev. 2012;92(4):1619\u201349.","journal-title":"Physiol Rev"},{"issue":"2","key":"2908_CR29","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.immuni.2017.01.004","volume":"46","author":"HN Nguyen","year":"2017","unstructured":"Nguyen HN, Noss EH, Mizoguchi F, et al. Autocrine Loop Involving IL-6 Family Member LIF, LIF Receptor, and STAT4 Drives Sustained Fibroblast Production of Inflammatory Mediators. Immunity. 2017;46(2):220\u201332.","journal-title":"Immunity"},{"issue":"6","key":"2908_CR30","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/s41584-020-0413-5","volume":"16","author":"G Nygaard","year":"2020","unstructured":"Nygaard G, Firestein GS. Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes. Nat Rev Rheumatol. 2020;16(6):316\u201333.","journal-title":"Nat Rev Rheumatol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02908-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-022-02908-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02908-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T10:12:48Z","timestamp":1663323168000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-022-02908-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,16]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2908"],"URL":"https:\/\/doi.org\/10.1186\/s13075-022-02908-5","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,16]]},"assertion":[{"value":"14 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Ethics Review Committee of the University of Occupational and Environmental Health, Japan, and written informed consent was obtained from all participants at the time of sample collection (H24-30). All animal experiments were approved by the Ethics Committee of Animal Care and Experimentation of the University of Occupational and Environmental Health, Japan, in accordance with the Guiding of Principle for Animal Care Experimentation (AE 14-025).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Mitsubishi Tanabe Pharma Corporation provided support in the form of salaries for K. Sakata. K. Nakano has received speaking fees from Astellas, UCB, Mitsubishi-Tanabe, Eisai and has received research grants from Mitsubishi-Tanabe, Eisai, and Eli Lilly. K. Ohmura has received speaking fees and\/or honoraria from Abbvie, Actelion, Astellas, Ayumi, Asahikasei-Pharma, Bristol-Myers, Eisai, Eli Lilly, GSK, Janssen, Mitsubishi Tanabe, Novartis, Sanofi and has received research grants from Bristol-Myers, Eisai, Eli Lilly, GSK, Mitsubishi-Tanabe, Nippon-Kayaku. S. Nakayamada has received speaking fees from Bristol-Myers, Sanofi, Abbvie, Eisai, Chugai, Pfizer, Takeda, Asahi-kasei and has received research grants from Mitsubishi-Tanabe, Novartis and MSD. Y. Tanaka has received speaking fees and\/or honoraria from Daiichi-Sankyo, Astellas, Chugai, Eli Lilly, Pfizer, Abbvie, YL Biologics, Bristol-Myers, Takeda, Mitsubishi-Tanabe, Novartis, Eisai, Janssen, Teijin and has received research grants from Asahi-kasei, Mitsubishi-Tanabe, Chugai, Takeda, Sanofi, Bristol-Myers, UCB, Daiichi-Sankyo, Eisai and Ono. All other authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"222"}}